Amanda Freese
Acute Care · Annapolis, MDNPI 1760994925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AOP Health US, LLC at 30.0% of the total. 2025 is the largest year on record at $1,346, 4.4 times the $308 reported in 2023. Among acute care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $29.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AOP Health US, LLC$695
- Actelion Pharmaceuticals US, Inc.$239
- Novartis$208
- Novo Nordisk$148
- Pfizer$139
- Esperion Therapeutics, Inc.$117
- plus $773 from 25 others
What the payments were for
- Food & beverage$2,318100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AOP Health US, LLC | 1 | $695 |
| Actelion Pharmaceuticals US, Inc. | 10 | $239 |
| Novartis | 10 | $208 |
| Novo Nordisk | 6 | $148 |
| Pfizer | 6 | $139 |
| Esperion Therapeutics, Inc. | 6 | $117 |
| AstraZeneca | 4 | $71 |
| Scpharmaceuticals Inc. | 4 | $66 |
| Johnson & Johnson | 2 | $59 |
| Atricure, Inc. | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Medicomp Inc | 2 | $45 |
| Cequr Corporation | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Boston Scientific | 2 | $37 |
| Argenx US, Inc. | 1 | $28 |
| Soleno Therapeutics, Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Merck | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$1,390
How this compares
$2,318 in reported general payments places this provider in the 90th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $134,718 |
| EntrestoSacubitril/Valsartan | 13 | $12,578 |
| Ranolazine ErRanolazine | 11 | $2,811 |
| Metoprolol Succinate | 94 | $1,689 |
| Amlodipine Besylate | 74 | $854 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 40 | $818 |
| Rosuvastatin Calcium | 33 | $793 |
| Atorvastatin Calcium | 46 | $722 |
| Losartan Potassium | 70 | $563 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $493 |
| Furosemide | 94 | $406 |
| Amiodarone Hcl | 12 | $347 |
| Potassium Chloride | 17 | $319 |
| Metoprolol Tartrate | 62 | $250 |
| Torsemide | 11 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $134,71898 claims |
| NovartisEntresto | $208 | $12,57813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 502 acute care providers in Maryland.
Other acute care in Annapolis
- Paige GriffithBaltimore$106K
- Amanda ReaPerry Hall$65K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Tierra AndersonTakoma Park$9K
- Lateaqua AlstonBaltimore$9K
- Norma FloresTowson$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.